Fate Therapeutics (FATE) Current Leases (2019 - 2026)

Fate Therapeutics (FATE) has 8 years of Current Leases data on file, last reported at $4.7 million in Q1 2026.

• Quarterly Current Leases fell 27.57% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 million (down 27.57% YoY) and the FY2025 annual result came in at $4.6 million, down 38.48% from the prior year.
• Current Leases advanced to $4.7 million in Q1 2026, from $4.6 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $7.4 million in Q4 2024 to a low of $4.6 million in Q4 2025.
• A 5-year average of $5.9 million and a median of $5.8 million in 2022 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2022 — Current Leases rose 26.52% — and 2025, when it slumped 38.48%.
• Tracing FATE's Current Leases over 5 years: stood at $5.6 million in 2022, then increased by 9.74% to $6.2 million in 2023, then rose by 20.08% to $7.4 million in 2024, then tumbled by 38.48% to $4.6 million in 2025, then rose by 3.9% to $4.7 million in 2026.
• The last three Current Leases figures came in at $4.7 million (Q1 2026), $4.6 million (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.